January 28, 2010
Prezista labeling updated to include 96-week data
At 96 weeks, Prezista was shown to be non-inferior to lopinavir/ritonavir. The ARTEMIS and TITAN 96-week study data showed that 78% and 58%, respectively, of patients in the Prezista/ritonavir arm reached an undetectable viral load compared to 74% and 52%, respectively, of patients in the lopinavir/ritonavir arm.
Prezista is indicated for the treatment of HIV infection in combination with ritonavir and with other antiretroviral agents.
For more information call (877) 732-2488 or visit www.prezista.com.